Posted by Michael Wonder on 12 Sep 2019
In U.S. biosimilars run into more roadblocks
12 September 2019 - In a recent op-ed in the Wall Street Journal Peter Bach asks whether it's time to give up on biosimilars.
One might counter by saying don't throw out the baby with the bathwater. While biosimilar uptake has not been as robust as was hoped initially, it's premature to throw in the towel.
On the regulatory front the news is encouraging. In the past few months there have been several high-profile approvals for the first biosimilars indicated to treat cancer in the U.S. This includes launches of Mvasi, which references Avastin (bevacizumab), and Kanjinta, which references Herceptin (trastuzumab), and the Food and Drug Administration's approval of Ruxience, which references Rituxan (rituximab).
